The document outlines the 2019 update to the South African guideline for managing chronic obstructive pulmonary disease (COPD). It emphasizes the importance of early diagnosis, prevention through smoking cessation, use of bronchodilators as primary pharmacotherapy, and a comprehensive approach to pa...tient care including pulmonary rehabilitation and the management of comorbidities. The guideline also covers recommendations for handling acute exacerbations, surgical interventions, and long-term treatment options.
more
The NICE guideline on antimicrobial prescribing for acute exacerbations of COPD provides recommendations for optimizing antibiotic use to treat exacerbations effectively while minimizing the risk of antimicrobial resistance. It includes criteria for assessing the need for antibiotics, guidance on se...lecting antibiotics, and considerations for reassessment and follow-up care.
more
The COPD Foundation's website provides a range of educational resources and downloadable materials aimed at helping patients, caregivers, and healthcare professionals learn more about COPD, including information on prevention, treatment, and disease management.
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, impr...ove quality of life and keep them healthy for longer.
more
The document discusses the complexities of managing patients with COPD and multiple comorbidities, highlighting the importance of personalized care and the appropriate use of inhaled corticosteroids (ICS). It outlines common comorbidities, such as asthma, osteoporosis, and diabetes, and offers guida...nce on optimizing treatment regimens while minimizing risks and polypharmacy in primary care settings.
more
The document "Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD)" from the IPCRG provides guidance on when to start, adjust, or discontinue ICS in COPD treatment. It highlights the benefits and risks, emphasizing personalized... treatment based on patient history, exacerbation frequency, and eosinophil count, while detailing how to optimize bronchodilator use to manage symptoms effectively.
more
The document is a visual guide created by the IPCRG for managing COPD, focusing on self-management, treatment options (such as inhaler use, pulmonary rehabilitation, and medications), and addressing comorbidities. It highlights the importance of personalized care plans, patient education, risk reduc...tion, vaccinations, and the correct use of therapies to improve quality of life and manage COPD effectively.
more
The International Primary Care Respiratory Group (IPCRG) is a clinically-led charitable company that works locally in primary care and collaborates globally to improve respiratory health. Our vision is that, through universal access to the right care, everyone can breathe and feel well.
The aim of the GOLD Report is to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of people with COPD. One of the strengths of GOLD reports is the treatment objectives. These have stood the test of time, and are organized into two groups: objectives tha...t are directed towards relieving and reducing the impact of symptoms, and objectives that reduce the risk of adverse health events that may affect the patient at some point in the future (exacerbations are an example of such events). This emphasizes the need for clinicians to focus on both the short-term and long-term impact of COPD on their patients.
more
Chronic Obstructive Pulmonary Disease (COPD) is now one of the top three causes of death worldwide and 90% of these deaths occur in low- and middle-income countries (LMICs).
More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. COPD represents an important public... health challenge that is both preventable and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years and die prematurely from it or its complications. Globally, the COPD burden is projected to increase incoming decades because of continued exposure to COPD risk factors and aging of thepopulation.
more
The document "Chronic Respiratory Diseases: A Handbook for Pharmacists" outlines the significant role pharmacists play in managing asthma and COPD, emphasizing patient education, disease prevention, medication management, and promoting healthy lifestyles. It highlights the importance of pharmacists ...in supporting early detection, adherence to treatment, smoking cessation, and interprofessional collaboration to enhance respiratory care and outcomes.
more
The document outlines a comprehensive package of interventions for the rehabilitation of cardiopulmonary conditions, emphasizing assessments, treatments, and support mechanisms aimed at improving patients' quality of life and functional ability, provided by a multidisciplinary team.
The NICE guideline NG114 provides recommendations on antimicrobial therapy for acute exacerbations of chronic obstructive pulmonary disease (COPD), aiming to optimize antibiotic use and minimize the development of antibiotic resistance.
The document provides a summary of recommendations for the non-pharmacological management of chronic obstructive pulmonary disease (COPD) and the use of inhaled therapies in individuals over 16, emphasizing confirmed diagnosis, treatment options, and regular review of treatment effectiveness and inh...aler technique.
more
Chronic obstructive pulmonary disease (COPD) is a complex disease that requires differential diagnosis and proper classification to identify appropriate therapy. Nonpharmacologic therapy and preventative measures should be utilized to prevent worsening of disease, symptoms, and complications. The Gl...obal Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classify a patient’s COPD and provide recommendations for first-line treatment. The 2021 update included information regarding the use of e-cigarettes as nicotine replacement, triple therapy, and how the SARS-CoV-2 virus impacted patients with COPD. This article will focus on the diagnosis, classification, and treatment of COPD, as well as recently updated information regarding the use of e-cigarettes and the impact of COVID-19.
more
The article provides a comprehensive overview of chronic obstructive pulmonary disease (COPD), covering its causes, symptoms, diagnostic methods, classification of severity, treatment options, and management strategies, with a focus on risk factors, clinical features, and therapeutic approaches such... as smoking cessation, bronchodilators, rehabilitation, and potential surgical interventions.
more
PATS and ERS
Paediatric Webinar Series
Paediatric Respiratory Reserch: meet the experts
The Indian Chest Society is a professional organization dedicated to promoting knowledge, research, and education in the field of pulmonology and respiratory diseases to enhance the diagnosis, treatment, and prevention of such conditions.
These podcasts are produced for educational discussions only. Reference to any specific product, treatment, or entity does not constitute an endorsement. The views expressed by speakers are their own and do not necessarily reflect the view of GOLD in entirety.
Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ...asthma. However, definitions of severity should encompass not merely doses of prescribed medication, but also underlying risk. The nature of asthmatic airway disease shows geographical variation, and LMIC asthma should not be assumed to be phenotypically the same as that in high-income countries (HICs). The first assessment step is to ensure another diagnosis is not being missed. Largely, political action is needed if children with asthma are to get access to basic medications. If a child is apparently not responding to low dose, simple medications, the next step is not to increase the dose but perform a detailed assessment of what factors (for example co-morbidities such as obesity, or social factors like poor adherence) are inhibiting a treatment response; in most cases, an underlying reason can be found. An assessment of risk of future severe asthma attacks, side-effects of medication and impaired lung development is also important. True severe, therapy-resistant asthma is rare and there are multiple underlying molecular pathologies. In HICs, steroid-resistant eosinophilia would be treated with omalizumab or mepolizumab, but the cost of these is prohibitive in LMICs, the biomarkers of successful therapy are likely only relevant to HICs. In LMICs, a raised blood eosinophil count may be due to parasites, so treating asthma based on the blood eosinophil count may not be appropriate in these settings.
more